Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus–diphtheria–acellular pertussis vaccine: a randomised, double-blind, phase 2b trial

Cheryl Keech, Vicki E. Miller, Barbara Rizzardi, Christopher Hoyle, Melinda J. Pryor, Jonathan Ferrand, Ken Solovay, Marcel Thalen, Stephanie Noviello, Peter A. Goldstein, Andrew Gorringe, Breeze E. Cavell, Qiushui He, Alex‐Mikael Barkoff, Keith Rubin, Camille Locht